Blood samples of 32 AD patients were obtained before, after 4 and 16 weeks of an anti‐IL‐4Rα antibody therapy (300 mg subcutaneously/2 weeks; n = 21) or AIT (daily sublingual application; n = 11). The gene discussed is IL4R; the disease is Alzheimer disease.